HC Wainwright Reiterates Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

HC Wainwright restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Monday, Benzinga reports. The firm currently has a $400.00 price target on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. Canaccord Genuity Group reaffirmed a buy rating and set a $283.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. William Blair reaffirmed an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Needham & Company LLC reissued a buy rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 2nd. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a report on Monday, April 29th. Finally, Chardan Capital restated a buy rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Eight research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of Moderate Buy and an average price target of $245.14.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $247.00 on Monday. The company’s 50 day simple moving average is $157.89 and its 200-day simple moving average is $164.23. The firm has a market capitalization of $31.24 billion, a PE ratio of -92.16 and a beta of 0.30. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same quarter last year, the business posted ($1.40) EPS. The firm’s revenue was up 54.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total value of $370,755.00. Following the completion of the transaction, the chief financial officer now owns 28,892 shares in the company, valued at approximately $6,674,052. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,357 shares of company stock valued at $13,436,711. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ALNY. Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $390,438,000. Capital International Investors lifted its stake in shares of Alnylam Pharmaceuticals by 15.8% in the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after acquiring an additional 488,814 shares during the period. Wellington Management Group LLP lifted its stake in shares of Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the period. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. Finally, Capital Research Global Investors lifted its stake in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.